NR3C1 and ovarian carcinoma: GR antagonists, such as mifepristone or relacorilant could reverse chemotherapy resistance and potentiate chemotherapy-induced apoptosis in triple-negative breast cancer, pancreatic cancer, and ovarian cancer cell lines [12,82].